HBV News and Research

RSS

Telbivudine drug prevents perinatal transmission of HBV

The antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV), according to a study in the June issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

2 Jun 2015

miR-181b potential biomarker of replication, progression in chronic HBV

A Chinese team reports a correlation between serum levels of microRNA-181b and hepatitis B virus replication and disease progression in patients with chronic HBV infection.

1 Jun 2015

TDF alone may be sufficient maintenance in chronic HBV patients

Tenofovir disoproxil fumarate monotherapy may be sufficient to maintain complete virological suppression in patients with chronic hepatitis B virus infection previously treated with TDF plus entecavir, suggests a review of patients.

1 Jun 2015

Meta-analysis sheds light on effectiveness of chronic HBV treatments

A meta-analysis of treatments for chronic hepatitis B virus infection suggests that tenofovir disoproxil fumarate is the most effective option for patients positive and negative for hepatitis B e antigen, but the latter group may also benefit from entecavir treatment.

1 Jun 2015

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center.

14 May 2015

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Matteo Iannacone of the San Raffaele Scientific Institute in Milan where intravital microscopy is being applied to the study of host-viruses and associated immune responses.

7 May 2015

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

5 May 2015

TDF switch effective in Asian chronic HBV patients

Switching therapy to tenofovir disoproxil fumarate is effective in treatment-resistant chronic hepatitis B, show results from a cohort of Asian patients.

29 Apr 2015

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

In patients with chronic hepatitis B virus infection, treatment with tenofovir disoproxil fumarate does not significantly increase the risk of developing renal dysfunction compared with entecavir treatment, a US team reports.

29 Apr 2015

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Tenofovir disoproxil fumarate alone elicits a response comparable to that of TDF plus entecavir in heavily pretreated patients with chronic hepatitis B virus infection resistant to adefovir dipivoxil, research suggests.

29 Apr 2015

Study highlights need to increase current levels of interventions to reduce HBV transmission

Results revealed today at The International Liver Congress 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible.

23 Apr 2015

Novel immunotherapeutic shows promise against chronic hepatitis B

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Researchers from Taiwan determined that individuals with human immunodeficiency virus (HIV) infection or those who inject illicit drugs have a higher risk of becoming infected with the hepatitis D virus (HDV) in that country.

22 Apr 2015

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Research suggests that virological, serological and histological outcomes are comparable between cirrhotic and noncirrhotic patients with chronic hepatitis B virus infection undergoing long-term tenofovir disoproxil fumarate treatment.

13 Apr 2015

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B.

26 Mar 2015

Long-term entecavir, TDF effective in chronic HBV in real-world setting

A Turkish clinical practice study shows that entecavir and tenofovir disoproxil fumarate can effectively maintain long-term virological and biochemical responses in patients with chronic hepatitis B virus infection, both in those with and without cirrhosis.

13 Mar 2015

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Hepatitis B surface antigen and hepatitis B core-related antigen levels can predict long-term response to sequential nucleos(t)ide analogue and interferon-α therapy in patients with chronic hepatitis B virus infection, research indicates.

13 Mar 2015

HBV genotype C HBeAg seroconversion rate ‘negligible’

Patients with chronic hepatitis B virus genotype C infection who are positive for hepatitis B e antigen should not delay antiviral treatment in the hope of seroconversion, Korean researchers recommend.

13 Mar 2015

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera.

11 Mar 2015

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

HBV News and Research

Telbivudine drug prevents perinatal transmission of HBV

miR-181b potential biomarker of replication, progression in chronic HBV

TDF alone may be sufficient maintenance in chronic HBV patients

Meta-analysis sheds light on effectiveness of chronic HBV treatments

MD Anderson researchers find significant clinical variations among liver cancer patients

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

TDF switch effective in Asian chronic HBV patients

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Study highlights need to increase current levels of interventions to reduce HBV transmission

Novel immunotherapeutic shows promise against chronic hepatitis B

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Study: HBV exposure increases immune system maturation of infants

Long-term entecavir, TDF effective in chronic HBV in real-world setting

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

HBV genotype C HBeAg seroconversion rate ‘negligible’

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News